Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Eupraxia Pharmaceuticals Inc. before investing.

In this article, we go over a few key elements for understanding Eupraxia Pharmaceuticals Inc.’s stock price such as:

• Eupraxia Pharmaceuticals Inc.’s current stock price and volume
• Why Eupraxia Pharmaceuticals Inc.’s stock price changed recently
• Upgrades and downgrades for EPRX from analysts
• EPRX’s stock price momentum as measured by its relative strength

About Eupraxia Pharmaceuticals Inc. (EPRX)

Before we jump into Eupraxia Pharmaceuticals Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company’s product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Want to learn more about Eupraxia Pharmaceuticals Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Eupraxia Pharmaceuticals Inc..

Eupraxia Pharmaceuticals Inc.’s Stock Price as of Market Close

As of June 18, 2026, 4:00 PM, CST, Eupraxia Pharmaceuticals Inc.’s stock price was $6.480.

Eupraxia Pharmaceuticals Inc. is up 3.02% from its previous closing price of $6.290.

During the last market session, Eupraxia Pharmaceuticals Inc.’s stock traded between $6.280 and $6.530. Currently, there are approximately 56.71 million shares outstanding for Eupraxia Pharmaceuticals Inc..

Eupraxia Pharmaceuticals Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Eupraxia Pharmaceuticals Inc. Stock Price History

Eupraxia Pharmaceuticals Inc.’s (EPRX) price is currently down 8.6% so far this month.

During the month of June, Eupraxia Pharmaceuticals Inc.’s stock price has reached a high of $7.230 and a low of $5.630.

Over the last year, Eupraxia Pharmaceuticals Inc. has hit prices as high as $9.320 and as low as $4.190. Year to date, Eupraxia Pharmaceuticals Inc.’s stock is down 14.17%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Eupraxia Pharmaceuticals Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of June 18, 2026,, no analysts have changed their rating of Eupraxia Pharmaceuticals Inc.’s stock over the last month.

Additionally, you'll want to evaluate Eupraxia Pharmaceuticals Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Eupraxia Pharmaceuticals Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Eupraxia Pharmaceuticals Inc. (EPRX) by visiting AAII Stock Evaluator.

Relative Price Strength of Eupraxia Pharmaceuticals Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 18, 2026, Eupraxia Pharmaceuticals Inc. has a weighted four-quarter relative price strength of 1.26%, which translates to a Momentum Score of 63 and is considered to be Strong.

Want to learn more about how Eupraxia Pharmaceuticals Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Eupraxia Pharmaceuticals Inc. Stock Price: Bottom Line

As of June 18, 2026, Eupraxia Pharmaceuticals Inc.’s stock price is $6.480, which is up 3.02% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Eupraxia Pharmaceuticals Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.